Cancer Biomarkers and Pharmacogenomics

Liquid biopsy uses non-solid biological tissue (e.g., blood) for prognosis and monitoring of various conditions, including cancer. In this series of collaborations with Erica L. Carpenter, MBA, PhD, we investigate various biomarkers – including and especially circulating tumor cells and cell-free DNA – for their capacity to provide early detection of disease or ability to improve prognosis. I provide statistical expertise
A collaboration with Erica L. Carpenter, MBA, PhD investigating the use of blood-based biomarkers for cancer prognosis.

Nicholas J. Seewald
Assistant Professor of Biostatistics
Assistant Professor of Biostatistics at the University of Pennsyvlania Perelman School of Medicine
Publications
Background: Recurrence after early-stage breast cancer (BC) is a challenge, occurring in ∼30% of patients (pts). Recurrences may arise …
Purpose: Non-invasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients …
Background: Patients with metastatic neuroendocrine tumor (NET) have multiple options for liver-directed therapy (LDT) and systemic …
Background: Pancreatic cancers (PDACs) with BRCA1/2 pathogenic variants (PVs) are prognostically favorable and predict response to …
Background: BRCA1/2 germline or somatic pathogenic variants (PVs) are found in 5-10% of pancreatic adenocarcinoma (PDAC) patients. …